US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816

Journal of Clinical Oncology

Volumn 34, Issue 17, 2016, Pages 2020-2027

  Press, Oliver W ^a,b   Li, Hongli ^a   Schöder, Heiko ^c   Straus, David J ^c   Moskowitz, Craig H ^c   LeBlanc, Michael ^a   Rimsza, Lisa M ^e   Bartlett, Nancy L ^f   Evens, Andrew M ^g   Mittra, Erik S ⁱ   LaCasce, Ann S ^h   Sweetenham, John W ^j   Barr, Paul M ^d   Fanale, Michelle A ^k   Knopp, Michael V ^l   Noy, Ariela ^c   Hsi, Eric D ^m   Cook, James R ^m   Lechowicz, Mary Jo ⁿ   Gascoyne, Randy D ^o   Leonard, John P ^c   Kahl, Brad S ^f   Cheson, Bruce D ^p   Fisher, Richard I ^q   Friedberg, Jonathan W ^d   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m LERNER RESEARCH INSTITUTE   (United States)

ⁿ EMORY UNIVERSITY   (United States)

^o BRITISH COLUMBIA CANCER AGENCY   (Canada)

^p GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^q FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVALUATION AND FOLLOW UP; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET-CT SCANNER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; SKIN CANCER; ADOLESCENT; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F18; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROCARBAZINE; RADIOPHARMACEUTICALS; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 84974678615     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.1119     Document Type: Article

References (28)

1. Press OW: Hodgkin lymphoma, in Kaushansky K, Lichtman M, Prchal J, et al (eds): Williams' Hematology (ed 9). New York, NY, McGraw Hill, 2016, pp 1603-1624
2. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003
3. Gordon LI, Hong F, Fisher RI, et al: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:684-691, 2013
4. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
5. Sieniawski M, Reineke T, Nogova L, et al: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study Group (GHSG). Blood 111:71-76, 2008
6. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007
7. Gallamini A, Kostakoglu L: Interim FDG-PET in Hodgkin lymphoma: A compass for a safe navigation in clinical trials? Blood 120:4913-4920, 2012
8. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
9. 18F-FDG PET in Hodgkin lymphoma: Would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med 54:1082-1093, 2013
10. Oki Y, Chuang H, Chasen B, et al: The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165:112-116, 2014
11. Boleti E, Mead GM: ABVD for Hodgkin's lymphoma: Full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 18:376-380, 2007
12. Evens AM, Cilley J, Ortiz T, et al: G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 137:545-552, 2007
13. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012
16. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
17. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
18. Diefenbach CS, Li H, Hong F, et al: Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-538, 2015
19. Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885, 2010
20. Scott DW, Chan FC, Hong F, et al: Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 31:692-700, 2013
21. Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048-3058, 2014
22. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3068, 2014
23. Gallamini A, Patti C, Viviani S, et al: Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 152:551-560, 2011
24. Kostakoglu L, Cheson BD: Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging 41:1004-1027, 2014
25. Johnson PW, Federico M, Fossa A, et al: Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: First analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033). Hematol Oncol 33, 2015 (suppl; abstr 108)
26. Raemaekers JM, André MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
27. Raemaekers JM: Early FDG-PET adapted treatment improves the outcome of early FDG-PET positive patients with stages I/II Hodgkin lymphoma (HL): Final results of the randomized intergroup EORTC/LYSA/FIL H10 trial. Presented at the 13th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 17-21, 2015, 2015
28. Radford J, Illidge T, Counsell N, et al: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 372:1598-1607, 2015